Is Berberine Good for Your Kidneys?

Animal research on berberine and kidney health is genuinely encouraging, with dozens of studies in rodents showing improvements in markers of kidney function across several different disease models. But the honest answer is that we do not yet have strong clinical evidence from human trials to confirm these effects in people. One small human trial in patients with type 2 diabetes found that adding berberine improved kidney-related blood markers, and a systematic review of animal data concluded that berberine improves key indicators of renal function in diabetic models. The gap between promising lab results and proven clinical benefit remains wide, and that gap matters if you are considering berberine specifically for your kidneys.

Where the Evidence Is Strongest: Diabetic Kidney Disease in Animals

The largest body of research on berberine and the kidneys centers on diabetic kidney disease, which is one of the leading causes of kidney failure worldwide. In diabetic animals, high blood sugar gradually damages the tiny filtering units in the kidneys. Berberine appears to push back against this damage through several overlapping mechanisms. A systematic review and meta-analysis pooling results from preclinical studies found that berberine improved standard markers of kidney function, including blood urea nitrogen, serum creatinine, proteinuria (protein leaking into urine), and kidney index scores.¹

Individual studies flesh out the picture. In diabetic rats, eight weeks of berberine at moderate doses significantly reduced blood urea nitrogen, serum creatinine, and urinary protein, performing comparably to captopril, a standard blood-pressure drug used to protect kidneys in diabetes.² In mice engineered to develop diabetes, berberine treatment reversed metabolic disorder and reduced the scarring of the kidney’s filtering structures. The mechanism involved restoring healthy energy production inside mitochondria and reducing fat buildup in podocytes, the specialized cells that form the kidney’s filtration barrier.³

A key pathway that keeps coming up is AMPK, an energy-sensing enzyme that cells use to manage stress. Berberine consistently activates AMPK in kidney cells, and when researchers block this activation, berberine’s kidney-protective effects disappear. This was demonstrated in cultured human kidney cells and confirmed in diabetic mice, suggesting AMPK is not just correlated with the benefit but required for it.⁴

Protecting Against Acute Kidney Injury

A separate line of research looks at berberine’s ability to shield the kidneys from sudden damage, particularly from cisplatin, a powerful chemotherapy drug notorious for causing kidney toxicity. In mice given cisplatin, berberine reduced creatinine and blood urea nitrogen levels in a dose-dependent way, meaning higher doses produced greater protection. Tissue samples showed less structural damage and lower levels of KIM-1, an early marker of kidney cell injury.⁵ Another study found that berberine dialed down oxidative stress and inflammation in cisplatin-treated animals, reducing the expression of inflammatory molecules and markers of cell death.⁶

A more recent study added an important detail: berberine’s protection in cisplatin-induced acute kidney injury depended on boosting autophagy, the cell’s internal recycling system that clears damaged components. When researchers used a chemical to block autophagy, berberine’s protective effects vanished, confirming the mechanism rather than just correlating with it.⁷ The same study noted that berberine upregulated the Klotho gene, which is associated with anti-aging effects in the kidney and declines in chronic kidney disease.

Ischemia-reperfusion injury, the damage that happens when blood flow to the kidney is temporarily cut off and then restored (common during certain surgeries or after blood clots), is another area where berberine has shown promise. In rat models, berberine and berberine nanoparticles both protected kidney tissue structurally and functionally, with the nanoparticle form performing better than standard berberine.⁸ Interestingly, part of this protection appeared to work through the gut: berberine reduced harmful bacteria in the intestines that produce inflammatory compounds, which then eased the kidney’s burden.⁹

Berberine and Kidney Fibrosis

Fibrosis, the buildup of scar tissue, is the final common pathway through which many kidney diseases progress to organ failure. Once enough healthy kidney tissue is replaced by scar tissue, the organ cannot do its job. Berberine appears to slow this process in animals. In diabetic rats with kidney fibrosis, berberine reduced the protein and gene expression of TGF-β, a master regulator of scarring, along with markers of the tissue transformation that leads to fibrosis.¹⁰ A 2024 review cataloging berberine’s anti-fibrotic effects across multiple organs found that it works through several different signaling pathways, which may explain why it seems to reduce scarring regardless of what caused the initial kidney damage.¹¹

The Gut-Kidney Connection

One of the more interesting angles in berberine research involves the gut microbiome. When kidneys begin to fail, they lose the ability to clear certain waste products that are actually produced by gut bacteria. These uremic toxins build up in the blood and further damage the kidneys, creating a vicious cycle. Berberine, which is poorly absorbed into the bloodstream and spends most of its time in the gut, appears to interrupt this cycle at its source.

A study in mice with chronic kidney disease found that berberine changed the composition of gut bacteria and reduced the production of p-cresol, a harmful compound made by intestinal microbes from the amino acid tyrosine. It also increased butyric acid-producing bacteria (which are generally considered beneficial) and lowered trimethylamine N-oxide, another compound linked to kidney damage.¹² This is a compelling finding because it suggests berberine’s low bioavailability, which is usually framed as a limitation, may actually be an advantage for kidney health. Most of the compound stays in the intestinal tract, right where these toxin-producing bacteria live.

Uric Acid and Kidney Stones

High uric acid is a risk factor for both gout and kidney damage, and berberine has shown effects on this front too. In mice with induced hyperuricemia, berberine lowered uric acid levels by suppressing xanthine oxidase (the enzyme that produces uric acid) and by reducing the activity of transporters in the kidney that reabsorb uric acid back into the blood.¹³ A separate mouse study confirmed that high-dose berberine inhibited a specific uric acid transporter (URAT1) in the kidney tubules, matching the effect of benzbromarone, a prescription drug used for gout.¹⁴

As for kidney stones specifically, a rat study found that berberine prevented and eliminated calcium oxalate crystal deposits in the kidney tubules through a combination of antioxidant, diuretic, and urine-alkalinizing effects. It also reduced the calcium content excreted in urine, which is significant because excess urinary calcium is a major driver of stone formation.¹⁵ Again, these are animal findings that have not been tested in human stone-formers.

Blood Pressure and Kidney Damage

Chronic high blood pressure is the second-leading cause of kidney failure after diabetes, and a few animal studies have examined whether berberine protects against this type of kidney damage. In spontaneously hypertensive rats, berberine delayed the onset and reduced the severity of high blood pressure while partially protecting the kidneys from the resulting damage.¹⁶ In rats fed a high-fat, high-salt, high-fructose diet designed to produce hypertension, four weeks of berberine significantly lowered blood pressure and reduced urinary protein, blood urea nitrogen, and serum creatinine, largely through boosting the body’s antioxidant defenses.¹⁷ In a model of kidney injury caused by atherosclerotic blockage of a renal artery, berberine reduced blood pressure, LDL cholesterol, urinary albumin, and oxidative stress markers after 12 weeks of treatment.¹⁸

The Human Evidence Gap

With all of the animal data pointing in an encouraging direction, the obvious question is whether this holds up in people. The honest answer is that we barely know. The most directly relevant human study enrolled patients with type 2 diabetes and added berberine to their existing treatment. After the treatment period, the berberine group had significantly lower urinary albumin-to-creatinine ratios (a key marker of kidney leakage) and lower serum cystatin C levels (a sensitive measure of how well the kidneys filter blood) compared to controls. Statistical analysis indicated that berberine’s effect on these kidney markers was independent of its blood-sugar-lowering effects, suggesting a direct kidney benefit.¹⁹

That is a meaningful finding, but it is one trial with a relatively small number of participants. No large randomized controlled trial has tested berberine specifically for kidney outcomes as a primary endpoint. The human trials that exist for berberine tend to focus on blood sugar, cholesterol, or metabolic syndrome, with kidney function measured only as a secondary outcome or safety check. Until larger, well-designed kidney-focused trials are completed, calling berberine a proven kidney treatment would outpace the science.

The Bioavailability Problem

One of the biggest challenges with berberine is that your body absorbs very little of it. In rats, the absolute bioavailability of oral berberine is roughly 0.37%, meaning that less than half a percent of what you swallow reaches the bloodstream.²⁰ The compound gets rapidly metabolized, and about a fifth of the dose is excreted in feces as a breakdown product called berberrubine. Berberine and its metabolites do concentrate in the liver and kidney at levels higher than what is found in plasma, which may partly explain why effects on those organs show up even with such low blood levels.

This bioavailability challenge has spurred research into improved delivery systems. A nanoparticle-based formulation of berberine performed better than free berberine in both a kidney ischemia model and a diabetic kidney model, reducing albuminuria and improving renal inflammation and fibrosis more effectively than either free berberine or metformin alone.²¹ These are still early-stage experiments, not products you can buy, but they signal that researchers see berberine’s potential as worth the engineering effort to overcome its absorption limitations.

Combining Berberine With Other Treatments

Several studies have looked at whether berberine adds value on top of existing medications. In diabetic mice, combining berberine with metformin produced stronger kidney protection than either drug alone, as evidenced by improved kidney function tests and less structural damage on tissue examination. The combination worked partly by suppressing kidney inflammation through a pathway that neither treatment fully controlled by itself.²² A bioavailability-enhanced berberine formulation also outperformed both standard berberine and metformin alone in diabetic mice, reducing the expansion of the mesangial matrix that clogs up the kidney’s filtering structures.²³

These combination findings are particularly relevant because many people interested in berberine are already taking medications for diabetes, high blood pressure, or cholesterol. In animal models, berberine does not appear to interfere with these drugs and may enhance their kidney-protective effects. But this brings a caution: berberine interacts with certain medications in humans, particularly drugs metabolized by the same liver enzymes. Anyone on prescription medications should talk to their doctor before adding berberine, especially because the supplement is not regulated the way drugs are and doses can vary between products.

Safety Considerations for the Kidneys

Berberine’s safety profile in human studies to date has generally been favorable at typical supplement doses (usually 500 to 1,500 mg per day), with gastrointestinal symptoms like cramping, diarrhea, and nausea being the most common complaints. There are no published reports of berberine itself causing kidney damage in humans. However, the European Food Safety Authority (EFSA) has flagged that we lack the kind of rigorous, multi-dose toxicity studies conducted according to standard guidelines that would be needed to fully characterize its long-term safety profile.²⁴ That assessment is still underway.

A separate concern with any herbal supplement is product quality. Reviews of herbal products have documented contamination with heavy metals, undisclosed pharmaceuticals, and misidentified plant ingredients.²⁵ Heavy metals are directly toxic to the kidneys, so a contaminated berberine supplement could theoretically harm the very organ you are trying to protect. Choosing products that have been third-party tested for purity is one way to reduce this risk, though it does not eliminate it entirely.

People with existing kidney disease should be especially cautious. The kidneys are responsible for clearing berberine’s metabolites, and impaired kidneys could allow these metabolites to accumulate in ways that have not been studied. No clinical trial has specifically enrolled patients with advanced chronic kidney disease to assess berberine’s safety in that population.

Podocyte Protection and Why It Matters

Podocytes are highly specialized cells that wrap around the tiny blood vessels in the kidney’s filtration units. They act as the final gatekeeper, preventing large molecules like proteins from leaking into the urine. Once podocytes are damaged, they do not regenerate well, and their loss is a major driver of progressive kidney disease. Berberine appears to protect podocytes in lab and animal settings through at least two distinct mechanisms.

In one study, berberine prevented damage to podocytes exposed to fatty acids by blocking a process called mitochondrial fission, where the cell’s energy-producing structures fragment into dysfunctional pieces. Berberine preserved the expression of proteins that hold podocytes together (nephrin, podocin) and suppressed markers of podocyte injury.²⁶ In diabetic mice, berberine reversed podocyte damage and the structural scarring of the glomeruli by restoring healthy mitochondrial energy production and promoting the burning of fatty acids that would otherwise accumulate and poison the cells.³

Podocyte protection is a particularly interesting angle because so few available treatments specifically target these cells. Most kidney drugs work by lowering blood pressure or blood sugar, helping the kidney indirectly. If berberine genuinely protects podocytes directly, that would represent a different kind of benefit. But as with everything else in this story, confirming that in humans remains the missing piece.